Maryland State Retirement & Pension System Buys Shares of 8,663 Krystal Biotech, Inc. (NASDAQ:KRYS)

Maryland State Retirement & Pension System bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 8,663 shares of the company’s stock, valued at approximately $1,591,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Key Financial Inc bought a new stake in shares of Krystal Biotech in the 2nd quarter valued at approximately $28,000. Crossmark Global Holdings Inc. purchased a new position in shares of Krystal Biotech during the second quarter valued at approximately $319,000. Principal Financial Group Inc. grew its stake in shares of Krystal Biotech by 1,972.0% during the second quarter. Principal Financial Group Inc. now owns 123,469 shares of the company’s stock valued at $22,674,000 after buying an additional 117,510 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Krystal Biotech by 3.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,461 shares of the company’s stock worth $819,000 after buying an additional 169 shares during the period. Finally, Legato Capital Management LLC bought a new stake in shares of Krystal Biotech during the 2nd quarter worth approximately $408,000. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Trading Down 0.1 %

KRYS traded down $0.10 on Friday, reaching $195.12. The company had a trading volume of 202,918 shares, compared to its average volume of 360,353. Krystal Biotech, Inc. has a one year low of $93.95 and a one year high of $219.34. The company has a fifty day moving average of $194.04 and a 200-day moving average of $173.39. The company has a market capitalization of $5.57 billion, a P/E ratio of 104.34 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.50 by $0.03. The company had revenue of $70.28 million during the quarter, compared to analysts’ expectations of $65.27 million. During the same period last year, the company earned ($1.25) earnings per share. Krystal Biotech’s revenue for the quarter was up 70283900.0% compared to the same quarter last year. Research analysts predict that Krystal Biotech, Inc. will post 2 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Chardan Capital boosted their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a report on Monday, August 5th. HC Wainwright lifted their price target on shares of Krystal Biotech from $200.00 to $221.00 and gave the stock a “buy” rating in a report on Wednesday. Citigroup reissued a “neutral” rating and set a $204.00 price objective (up from $195.00) on shares of Krystal Biotech in a report on Tuesday, August 6th. Evercore ISI boosted their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a report on Monday, August 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a report on Thursday. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Krystal Biotech has an average rating of “Moderate Buy” and an average price target of $190.22.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the sale, the insider now directly owns 1,525,882 shares of the company’s stock, valued at approximately $268,189,020.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 14.10% of the company’s stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).